Clinical Trial Update: Study Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports the completion of a study comparing three new Premarin 0.625 mg/MPA 2.5 mg formulations with a reference formulation for menop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause

Drugs mentioned

• Premarin 0.625 mg/MPA 2.5 mg (conjugated estrogens/medroxyprogesterone acetate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Menopause | Phase 1 | Status: COMPLETED